Friday, Nov 20, 2026
Export LLY’s income statement to Excel — free account
Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
1,355.27
3.62
+0.27%
Follow LLY
Alert me
Q3 2026 quarterly report Eli Lilly cut its full-year earnings guidance, one of four health-care companies to do so as government funding and drug pricing changed. Read it in the report
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 21,222 | 19,974 | 21,493 | 22,320 | 24,540 | 28,318 | 28,541 | 34,124 | 45,043 | 65,179 | 86,461 | +13.3% | 91,668 | 106,485 | 118,924 | +22.2% | |
| Gross margin, % | 73.09 | 77.73 | 78.22 | 78.85 | 77.66 | 74.18 | 76.77 | 79.25 | 81.31 | 83.04 | 83.64 | +10.0 pt | ||||||
| EBT | 3,374 | 2,305 | 3,680 | 5,266 | 7,230 | 6,156 | 6,806 | 6,554 | 12,680 | 25,731 | 34,768 | +25.3% | ||||||
| EBT margin, % | 15.90 | 11.54 | 17.12 | 23.59 | 29.46 | 21.74 | 23.85 | 19.21 | 28.15 | 39.48 | 40.21 | +23.6 pt | ||||||
| Net income | 2,738 | (204) | 3,232 | 8,318 | 6,194 | 5,582 | 6,245 | 5,240 | 10,590 | 20,640 | 27,580 | +25.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 20.05 | 18.99 | 20.91 | 23.97 | 27.04 | 31.22 | 31.65 | 37.91 | 50.01 | 72.64 | 96.94 | +15.4% | |||||
| Earnings | 2.58 | (0.19) | 3.13 | 8.89 | 6.79 | 6.12 | 6.90 | 5.80 | 11.71 | 22.95 | 30.81 | +27.5% | ||||||
| Cash flow | 4.58 | 5.34 | 5.38 | 5.19 | 7.16 | 8.12 | 8.41 | 4.71 | 9.79 | 18.74 | 34.36 | +16.9% | ||||||
| Capex | (0.91) | (1.02) | (1.18) | (1.11) | (1.53) | (1.44) | (2.06) | (3.83) | (5.62) | (8.74) | (12.32) | +28.6% | ||||||
| Free cash flow | 3.67 | 4.31 | 4.20 | 4.08 | 5.63 | 6.68 | 6.36 | 0.88 | 4.18 | 10.00 | 22.04 | +11.8% | ||||||
| Book value | 13.30 | 11.09 | 10.61 | 2.90 | 6.42 | 10.09 | 11.95 | 12.07 | 15.85 | 29.57 | 45.15 | +9.3% | ||||||
| Shares, m | 1,058 | 1,052 | 1,028 | 931 | 908 | 907 | 902 | 900 | 901 | 897 | 894 | (1.8%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 28.91 | 0.00 | 36.97 | 14.97 | 24.83 | 44.99 | 52.90 | 102.10 | 65.93 | 46.83 | 43.87 | 41.8 | |||||
| P/S | 3.72 | 4.46 | 5.53 | 5.48 | 6.24 | 8.85 | 11.53 | 15.62 | 15.44 | 14.79 | 13.94 | 9.2 | ||||||
| P/B | 5.61 | 7.64 | 10.90 | 45.34 | 26.31 | 27.37 | 30.54 | 49.07 | 48.72 | 36.34 | 29.94 | 28.8 | ||||||
| EV/Sales | 3.83 | 4.56 | 5.62 | 6.07 | 6.77 | 9.30 | 12.02 | 16.14 | 16.02 | 15.34 | 14.51 | 9.6 | ||||||
| EV/FCF | 18.92 | 18.39 | 25.56 | 32.13 | 30.09 | 40.75 | 59.19 | 223.69 | 121.06 | 89.46 | 57.39 | 65.9 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 4,851 | 5,616 | 5,525 | 4,837 | 6,500 | 7,366 | 7,586 | 4,240 | 8,818 | 16,813 | 30,645 | +14.8% | |||||
| Capex | (964) | (1,077) | (1,211) | (1,034) | (1,388) | (1,310) | (1,854) | (3,448) | (5,058) | (7,841) | (10,984) | +26.2% | ||||||
| Free cash flow | 3,887 | 4,539 | 4,314 | 3,803 | 5,112 | 6,056 | 5,731 | 792 | 3,760 | 8,972 | 19,661 | +9.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 4,115 | 4,666 | 8,662 | 1,934 | 4,981 | 3,400 | 896 | (1,566) | 4,364 | 20,401 | 18,267 | +19.5% | |||||
| Net debt | 4,266 | 5,613 | 2,890 | 13,000 | 12,914 | 11,438 | 12,526 | 15,393 | 25,259 | 33,600 | 42,101 | +25.8% | ||||||
| Shareholders’ equity | 14,081 | 11,668 | 10,909 | 2,699 | 5,825 | 9,155 | 10,775 | 10,864 | 14,272 | 26,535 | 40,271 | +7.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 7.36 | (0.49) | 7.27 | 20.00 | 14.42 | 11.70 | 12.71 | 9.23 | 14.84 | 21.59 | 20.97 | +14.2 pt | |||||
| ROIC | 11.11 | 7.25 | 16.01 | 19.80 | 20.20 | 19.29 | 19.12 | 15.37 | 20.39 | 27.34 | 26.42 | +16.2 pt | ||||||
| ROE | 19.10 | (1.59) | 28.63 | 122.26 | 145.32 | 74.52 | 62.67 | 48.43 | 84.26 | 101.16 | 86.02 | +82.1 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 41,975 | 40,655 | 38,680 | 33,625 | 35,000 | 35,000 | 39,000 | 43,000 | 47,000 | 50,000 | — | +2.0% | |||||
| Revenue/emp, $m | 0.51 | 0.49 | 0.56 | 0.66 | 0.70 | 0.81 | 0.73 | 0.79 | 0.96 | 1.30 | — | +11.1% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026
Business profile
Where the money comes from and where it goes Fiscal 2025
| Reportable Segment | 65,179 | 100.00% |
|---|---|---|
| Gross margin | 83.04% | |
| Operating margin | 40.35% | |
| Pre-tax margin | 39.48% |
Eli Lilly and Company vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | $1.27T | 43.9× | 42.2× FY26e | +38.61% (above 0%: growing) | +16.26% (above 0%: growing) | +21.80% (above 0%: growing) | 83.88% | 36.52% | |
| JNJ Johnson & Johnson | $650.7B | 40.5× | 41.8× FY26e | +5.86% (above 0%: growing) | −95.75% (below 0%: shrinking) | −21.44% (below 0%: shrinking) | 68.12% | 1.72% | Compare |
| ABBV AbbVie Inc. | $501.2B | 48.8× | 37.6× FY26e | +10.32% (above 0%: growing) | +2,270.00% (above 0%: growing) | +9.97% (above 0%: growing) | 75.38% | 36.01% | Compare |
| MRK Merck & Co., Inc. | $328.6B | 137× | 105× FY26e | +4.68% (above 0%: growing) | −12.07% (below 0%: shrinking) | −19.27% (below 0%: shrinking) | 72.95% | 31.90% | Compare |
| NVS Novartis AG | $277.7B | 28.8× | 24.0× FY26e | +4.67% (above 0%: growing) | −68.81% (below 0%: shrinking) | −17.81% (below 0%: shrinking) | 75.99% | 12.26% | Compare |
| AZN AstraZeneca PLC | $272.1B | 24.6× | 24.2× FY26e | +6.70% (above 0%: growing) | +23.46% (above 0%: growing) | +1.99% (above 0%: growing) | 81.82% | 27.07% | Compare |
| AMGN Amgen Inc. | $237.4B | 25.2× | 24.0× FY26e | +8.45% (above 0%: growing) | +19.39% (above 0%: growing) | −13.98% (below 0%: shrinking) | 73.10% | 35.79% | Compare |
| GILD Gilead Sciences, Inc. | $207.8B | — (loss-making) | — (loss-making) | +6.83% (above 0%: growing) | −20.16% (below 0%: shrinking) | +21.13% (above 0%: growing) | 81.07% | 41.71% | Compare |
| PFE Pfizer Inc. | $158.2B | 38.8× | 18.7× FY26e | −0.43% (below 0%: shrinking) | −9.68% (below 0%: shrinking) | +20.02% (above 0%: growing) | 75.71% | 22.14% | Compare |
| Median of peers | $274.9B | 38.8× | 24.2× | +6.28% | −10.87% | −5.99% | 75.55% | 29.49% |
From the latest earnings call
- CEO David Ricks said more than 500,000 people had filled a Lilly prescription through the Medicare GLP-1 Bridge program since its July launch.
- CFO Lucas Montarce said Lilly expects volume growth to more than offset lower net realized prices in 2027, alongside a full year of Medicare Bridge access.
Largest institutional holders 13F, quarter to Jun 30, 2026
Held by institutions
83.46%
Held by the ten largest
47.82%
| Holder | Shares | Stake | Change |
|---|---|---|---|
| LILLY ENDOWMENT INC | 90.38m | 9.60% | −1.52m |
| Vanguard | 82.81m | 8.80% | +180.78k |
| BlackRock | 67.54m | 7.17% | +1.16m |
| PNC | 51.32m | 5.45% | −6.19k |
| Capital Group | 42.97m | 4.56% | −3.85m |
| State Street | 36.22m | 3.85% | +605.75k |
| Fidelity (FMR) | 28.46m | 3.02% | +2.12m |
| Geode Capital Management | 20.31m | 2.16% | +118.99k |
| Morgan Stanley | 16.23m | 1.72% | +788.94k |
| T. Rowe Price | 13.96m | 1.48% | −1.06m |
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.
Pay and ownership Proxy statement filed Mar 20, 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 36.70m | 75.19m | 670.56 |
| 2024 | 29.24m | 80.58m | 478.17 |
| 2023 | 26.57m | 120.87m | 358.72 |
| 2022 | 21.40m | 64.09m | 222.94 |
| 2021 | 21.51m | 75.71m | 166.08 |
Ownership
Directors and executive officers, together
less than 1%
Lilly Endowment Inc. (the Endowment)
9.80%
The Vanguard Group
8.60%
BlackRock, Inc.
6.80%
The PNC Financial Services Group, Inc.
5.40%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
Eli Lilly and Company (LLY) Latest News
What happened
- Results Eli Lilly reported third-quarter revenue of $24.4 billion and raised its 2026 revenue guidance to $91 billion–$92 billion.
- Deal Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, including upfront and milestone payments.
- Deal Eli Lilly partnered with Hims & Hers to offer Zepbound and Foundayo through its digital platform at self-pay prices.
- Product Eli Lilly received China’s first approval for an oral GLP-1 weight-loss drug with orforglipron.
- Product Eli Lilly reported that Foundayo reduced sleep apnea severity in a Phase 3 trial and plans to seek FDA review by the end of 2026.
- Health Canada approves Lilly's Mounjaro® (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes CNW Group
- Where Will Eli Lilly Be in 10 Years? 1 Clue: Its Next Potential Blockbuster Just Beat Ozempic Head-to-Head The Motley Fool
- What Does Eli Lilly (LLY) Reveal At ObesityWeek 2026 About Its Growth Path? Simply Wall St +1 report
- Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020 PR Newswire
- Baron Funds Sees Eli Lilly’s (LLY) Mounjaro, Zepbound and Orforglipron as Transformational Insider Monkey
- Eli Lilly and Company (LLY) Grew Revenue 48% as GLP-1 Demand Accelerated: Can Growth Continue? Insider Monkey
- Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy? The Motley Fool
- Eli Lilly Stock: Is Wall Street Bullish or Bearish? Barchart
- Is Eli Lilly Stock Worth More Than Its Competitors? Trefis
- Prediction: The Weight-Loss Drug Boom Could Be Just the Beginning for Lilly 24/7 Wall St.
3 more headlines
LLY metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
Eli Lilly discovers, develops, manufactures and markets medicines for people. Founded in 1875 and headquartered in Indianapolis, it is led by Chair, President and Chief Executive Officer David Ricks. Lilly operates as one business segment: human pharmaceutical products.
Its cardiometabolic medicines include Mounjaro for type 2 diabetes and Zepbound for obesity or overweight with a weight-related condition. Zepbound is also used to treat moderate to severe obstructive sleep apnea in adults with obesity. Lilly sells insulin products and collaborates with Boehringer Ingelheim on Jardiance, which has diabetes, heart failure and chronic kidney disease indications.